Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(11 sites)
China
The First Affiliated Hospital of USTC, Hefei, Anhui Sanbo Brain Hospital Capital Medical University, Beijing, Beijing Municipality The Cancer Hospital Affiliated to Chongqing University, Chongqing, Chongqing Municipality Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Shenzhen Second People's Hospital, Shenzhen, Guangdong The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong Guangxi Medical University Cancer Hospital, Nanning, Guangxi Qilu Hospital of Shandong University, Jinan, Shandong Tangdu Hospital of Air Force Medical University of the PLA, Xi’an, Shanxi The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang